Atezolizumab + Bevacizumab for Endometrial Cancer

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Kathleen Moore, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Oklahoma

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.

Eligibility Criteria

This trial is for women with advanced, recurrent or persistent endometrial cancer who have tried at least one platinum-based chemotherapy but no more than two regimens. Participants must be over 18, understand the study and consent to it, have measurable disease by certain medical imaging standards, an ECOG performance status of 0-2, and agree to use contraception if of childbearing potential.

Inclusion Criteria

For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods as defined in study protocol

Must have ability to comply with the study protocol, in the investigator's judgment

My endometrial cancer is advanced, recurrent, or persistent and does not respond to standard treatments.

Exclusion Criteria

I started taking corticosteroids not more than a week ago.

I have brain metastases but meet specific treatment criteria.

Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

Participant Groups

The trial is testing a combination of two drugs: Atezolizumab and Bevacizumab in women with specific types of endometrial cancer. It's a Phase II study focusing on the safety and effectiveness (futility) of this drug combo without comparing it to other treatments.

Group I: Bevacizumab + Atezolizumab Experimental Treatment 2 Interventions

Atezolizumab is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

🇪🇺 Approved in European Union as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

UAB Women and Infants Center Birmingham, AL

Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK

Washington University School of Medicine Saint Louis, MO

Who Is Running the Clinical Trial?

University of Oklahoma Lead Sponsor

Genentech, Inc. Industry Sponsor

References